Albany, NY -- (SBWIRE) -- 08/14/2018 -- Thrombocythemia is also referred as essential thrombocythemia or primary thrombocythemia. Thrombocythemia is a rare chronic blood clotting disorder caused by bone marrow. It is a condition in which blood has higher platelets compare to normal platelets. The normal range of platelet in human blood is 150,000 to 450,000 per microliter. Blood clots can occur suddenly in patients suffering from thrombocythemia. Abnormal blood clotting can be fatal as it may block the flow of blood to the heart, brain, liver, or other organs.
According to research, thrombocythemia is common in women and people over 50 years of age. Headache, chest pain, lightheadedness or dizziness, slightly enlarged spleen, fainting, changes in vision, weakness, numbness or tingling in feet or hands, redness, or throbbing are the common symptoms of thrombocythemia. Discharge of blood in urine, getting bruised easily, bleeding from nose or gums or mouth, or discharge of blood in stool are the rare symptoms of primary thrombocythemia. Shortness of breath, seizures, weakness or numbness in arm, leg, or face, or heart attack are high risk complications for thrombocythemia.
A complete blood count (CBC), blood smear, genetic testing (JAK2, CALR, or MPL gene), bone marrow aspiration, uric acid level are studied by healthcare professionals in order to diagnose thrombocythemia. Medical treatment of thrombocythemia depends on the severity of the disorder. Currently, hydroxyurea, anagrelide, interferon alfa, and low-dose aspirin are used commonly used for the treatment of thrombocythemia. In case of emergency, plateletpheres is also used to treat thrombocythemia. General prevalence of thrombocythemia is approximately 30 in 100,000 persons. Rise in prevalence of thrombocythemia in the geriatric population drive the Thrombocythemia Drug Market globally.
Request to View Brochure of Report -
https://www.transparencymarketresearch.com/sample/sample.php?flag=B&rep_id=37859
The global thrombocythemia drugs market can be segmented based on medical treatment and region. In terms of medical treatment, the thrombocythemia drug market can be categorized into anti-platelet treatment, platelet-lowering treatment, alternative cytoreductive therapy, and others. Aspirin is the gold standard treatment of thrombocythemia. It reduces the symptoms of declined platelets count. Hydroxyurea is platelet-lowering treatment for thrombocythemia subjects. Interferon-? (IFN-?) also offers significant results in reducing the platelet number. Pipobroman is an alternative cytoreductive therapy which is proposed to control the platelet number in elderly patients with essential thrombocythemia. In terms of revenue, the anti-platelet treatment and platelet-lowering treatment segments hold major shares of the thrombocythemia drugs market globally.
Key players operating in the global thrombocythemia drugs market are AstraZeneca plc, Intas Pharmaceuticals Ltd., Shire plc, Torrent Pharms Ltd., Teva Pharmaceutical Industries Ltd., Impax Laboratories, Inc., Otsuka Pharmaceutical Co., Ltd., Sandoz (Novartis AG), Luitpold Pharms Inc., Zydus Healthcare Ltd., and Cipla, Inc.
Enquiry for discount on this report -
https://www.transparencymarketresearch.com/sample/sample.php?flag=D&rep_id=37859